Kathryn C. Arbour

Oncology

530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: September 02, 2026

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

Journal: Future oncology (London, England)

Published: April 06, 2026

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 21, 2025

Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.

Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 11, 2025

Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.

Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.

Journal: Cancer discovery

Published: August 28, 2025

RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.

RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 07, 2025

Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC.

Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: July 22, 2025

Disrupted molecular glue complex drives RAS inhibitor resistance.

Disrupted molecular glue complex drives RAS inhibitor resistance.

Journal: Cell

Published: June 03, 2025

MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.

MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.

Journal: Cancer research

Published: May 20, 2025

The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.

The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.

Journal: Journal of the National Cancer Institute

Published: April 24, 2025

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Journal: Nature

Published: February 27, 2025

Showing 1-12 of 58

Last Updated: 09/26/2026